Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
56 hedge funds and large institutions have $98M invested in Kindred Biosciences, Inc. in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 10 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
0% more funds holding
Funds holding: 56 → 56 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
6.55% less ownership
Funds ownership: 60.29% → 53.74% (-6.5%)
56% less capital invested
Capital invested by funds: $222M → $98M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$9.8M |
| 2 |
Morgan Stanley
New York
|
+$3.42M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$3.38M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.38M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.1M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.65M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$1.63M |
| 5 |
Jane Street
New York
|
-$750K |
KIN Hedge Fund Activity: Q3 2014 in Review
56 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2014, worth a combined $98M — down 56% from $222M a quarter earlier.
Fund positioning in KIN was balanced in Q3 2014: 10 funds opened new positions, 10 closed out, 27 added to existing stakes and 13 trimmed.
The largest buyer was Jennison Associates, adding an estimated $9.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $40.3M sold.
- 56 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $98M of Kindred Biosciences, Inc. stock for Q3 2014, down 56% quarter-over-quarter.
- 10 funds opened new Kindred Biosciences, Inc. positions in Q3 2014 and 10 closed out, a net change of 0 holders.
- The largest Kindred Biosciences, Inc. buyer in Q3 2014 was Jennison Associates, an estimated $9.8M added.
- The largest Kindred Biosciences, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $40.3M sold.
Based on aggregated 13F filings for Q3 2014.